Under the leadership of John DeLuca, PhD, senior VP for Research & Training, and Nancy Chiaravalloti, PhD, director of Neuropsychology & Neuroscience Research, scientists have made important contributions to
the knowledge of cognitive decline in MS and developed new treatments.
Under the leadership of John DeLuca, PhD, senior VP of Research & Training, and Nancy Chiaravalloti, PhD, director of Neuropsychology & Neuroscience and TBI Research, scientists have made important contributions to
the knowledge of cognitive decline in MS. Clinical studies span new learning, memory, executive function, attention and processing speed, emotional processing and cognitive fatigue.
Under the leadership of John DeLuca, PhD, senior VP for Research & Training, and Nancy Chiaravalloti, PhD, director of Neuropsychology & Neuroscience Research, scientists have made important contributions to
the knowledge of cognitive decline in MS. Clinical studies span new learning, memory, executive function, attention and processing speed, emotional processing, employment and cognitive fatigue.
Not exact matches
Fernando Pagan, a GUMC associate professor
of neurology who directs the Movement Disorders Program at MedStar Georgetown University Hospital, said that to his
knowledge, the study «represents the first time a therapy appears to reverse — to a greater or lesser degree depending on stage
of disease —
cognitive and motor
decline in patients with these neurodegenerative disorders.»
The problem
of moral
decline is volitional, not
cognitive; it has little to do with
knowledge.
This reflects the increasing understanding that in rapidly changing
knowledge economies, critical thinking and problem solving are important parts
of the new global skill set, whereas the labor market demand for routine
cognitive competencies — the kinds
of skills that are easy to teach and test — has
declined rapidly over recent decades.
To date, the immediate and lasting positive effects
of quality care on language,
cognitive development, and school achievement have been confirmed by converging findings from large, reasonably representative longitudinal studies and smaller, randomized trials with long - term follow - ups.1, 2,9 - 13 Contributors to this
knowledge base include meta - analytic reviews
of interventions and large longitudinal studies conducted in several countries.1, 2,14,15 Comprehensive meta - analyses now establish that effects
of early care
decline, but do not disappear, and when initial effects are large, long - term effects remain substantial.1, 2 Null findings in
cognitive and social domains in a few studies may reasonably be attributed to the limitations inherent to their designs, samples, and measures.